Allianz Asset Management GmbH Buys 11,032 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Allianz Asset Management GmbH raised its stake in Royalty Pharma plc (NASDAQ:RPRXGet Rating) by 65.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,917 shares of the biopharmaceutical company’s stock after acquiring an additional 11,032 shares during the quarter. Allianz Asset Management GmbH’s holdings in Royalty Pharma were worth $1,113,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Deutsche Bank AG raised its holdings in Royalty Pharma by 36.5% in the 4th quarter. Deutsche Bank AG now owns 431,096 shares of the biopharmaceutical company’s stock valued at $17,179,000 after buying an additional 115,190 shares during the last quarter. California State Teachers Retirement System raised its holdings in Royalty Pharma by 36.5% in the 4th quarter. California State Teachers Retirement System now owns 596,869 shares of the biopharmaceutical company’s stock valued at $23,785,000 after buying an additional 159,681 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Royalty Pharma by 17.1% in the 4th quarter. Parametric Portfolio Associates LLC now owns 369,679 shares of the biopharmaceutical company’s stock valued at $14,732,000 after buying an additional 54,031 shares during the last quarter. Horizon Kinetics Asset Management LLC raised its holdings in Royalty Pharma by 17.6% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 282,537 shares of the biopharmaceutical company’s stock valued at $11,259,000 after buying an additional 42,209 shares during the last quarter. Finally, PACK Private Wealth LLC bought a new position in Royalty Pharma in the 4th quarter valued at approximately $476,000. 51.68% of the stock is owned by hedge funds and other institutional investors.

In other Royalty Pharma news, Director Rory B. Riggs sold 129,222 shares of the stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $39.55, for a total value of $5,110,730.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Henry A. Fernandez bought 32,500 shares of Royalty Pharma stock in a transaction dated Thursday, February 24th. The shares were bought at an average cost of $37.49 per share, with a total value of $1,218,425.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 252,422 shares of company stock valued at $9,912,757. Company insiders own 25.86% of the company’s stock.

RPRX has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a report on Wednesday, April 27th. They issued a “buy” rating and a $56.00 price objective for the company. Scotiabank initiated coverage on shares of Royalty Pharma in a research report on Friday. They set an “outperform” rating and a $53.00 target price for the company. Zacks Investment Research downgraded shares of Royalty Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. StockNews.com initiated coverage on shares of Royalty Pharma in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, JPMorgan Chase & Co. raised shares of Royalty Pharma from a “neutral” rating to an “overweight” rating and set a $50.00 target price for the company in a research report on Thursday, April 14th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Royalty Pharma has a consensus rating of “Buy” and an average price target of $49.43.

NASDAQ RPRX traded up $1.10 during mid-day trading on Tuesday, hitting $41.36. The company’s stock had a trading volume of 2,637,209 shares, compared to its average volume of 1,962,708. The company’s 50 day simple moving average is $40.57 and its 200 day simple moving average is $39.99. Royalty Pharma plc has a twelve month low of $34.86 and a twelve month high of $47.10. The company has a current ratio of 21.95, a quick ratio of 21.95 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $25.11 billion, a price-to-earnings ratio of 41.36, a PEG ratio of 1.09 and a beta of 0.35.

Royalty Pharma (NASDAQ:RPRXGet Rating) last announced its earnings results on Tuesday, February 15th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Royalty Pharma had a net margin of 26.46% and a return on equity of 16.75%. The company had revenue of $543.00 million during the quarter, compared to the consensus estimate of $543.50 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. As a group, research analysts forecast that Royalty Pharma plc will post 3 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 15th. Shareholders of record on Friday, May 20th will be paid a $0.19 dividend. The ex-dividend date of this dividend is Thursday, May 19th. This represents a $0.76 annualized dividend and a yield of 1.84%. Royalty Pharma’s dividend payout ratio (DPR) is 76.00%.

About Royalty Pharma (Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Stories

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRXGet Rating).

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.